Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
18   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present as panelist at KoNECT-KDDF GLOBAL CLINICAL DEVELOPMENT FORUM on August 17th, 2017.   Admin   2019-01-14   928  
17   Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab phase IIa recurrent GBM trial at 2017 SNO (Society for Neuro Oncology) meeting in San Francisco on November 16   Admin   2019-01-14   3,867  
16   PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by KIAT.   Admin   2019-01-14   60,344  
15   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present for ``Investor Relation`` at MIRAE ASSET DAEWOO SECURITIES Corporate Day on July 12th, 2017.   Admin   2019-01-14   981  
14   Interview of Dr. Jin-San Yoo, CEO of PharmAbcine with Bio-Pod   Admin   2019-01-14   1,407  
13   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting at the forum for future pharm in Seoul on June 23, 2017.   Admin   2019-01-14   1,013  
12   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting PharmAbcine`s R&D progress and the interim data of the ongoing phase IIa recurrent GBM trial at 2017 Bio International Convention in San Diego on June 19-22, 2017.   Admin   2019-01-14   1,615  
11   Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.   Admin   2019-01-14   1,314  
10   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D progress at BIO LOGISTICS WORLD KOREA in Seoul on May 23-24, 2017.   Admin   2019-01-14   1,359  
9   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an expert of MAB working group of EDQM observer representing Republic of Korea.   Admin   2019-01-14   1,357